Novo’s Wegovy notches second CV win, with a third readout due in 4Q

Evidence continues to mount for the cardiovascular benefits of Novo’s weight loss blockbuster Wegovy.

On Friday, Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) announced that Wegovy semaglutide met the co-primary endpoints in the Phase III STEP HFpEF trial, which tested the therapy in 529 obese patients with symptomatic heart failure with preserved ejection fraction (HFpEF). The study’s endpoints were weight loss and improvement in KCCQ-CSS score, which measures patients’ symptoms and physical limitations. Novo reported 10.7% placebo-adjusted weight loss, and p-values of <0.001 for both endpoints. ...